At a glance
ClinicalIndex Comparison RecordN/ACompleted· 122 enrolled
Drug / intervention
Stereotactic Body Radiotherapy (SABR)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
In Brief
A clinical study evaluating Stereotactic Body Radiotherapy (SABR) for Lung Cancer. Completed, enrolled 122 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC. Specifically, researchers want to learn if standard SRT has as good of an outcome at 3 years after the procedure. The safety of the study treatment will also be analyzed.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsVarian Medical Systems
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedFeb 2015
Primary CompletionSep 2021
TodayJul 2026
First PostedFeb 6, 2015
Enrollment StartApr 5, 2010
Primary CompletionSep 17, 2021
TodayJul 2, 2026
Enrollment to primary: 11.5 yearsPosted 11.4 years ago
Interventions
Stereotactic Body Radiotherapy (SABR)radiation
SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.